Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have a diagnosis of the following autoimmune cytopenias:~   immune thromobocytopenia purpura (ITP) autoimmune hemolytic anemia (AIHA) autoimmune neutropenia (AIN) pure red cell aplasia (PRCA) and~2. Patients must have refractory disease according to the following criteria~   1. not respond to steroids or~  2. need prednisolone more than 15 mg/d for maintenance therapy~3. Complete work up for baseline evaluation and measurement~4. Age \> 18 years~5. Patient's free written inform consent~Exclusion Criteria:~1. Patients with a known hypersensitivity to murine proteins or to any component of alemtuzumab~2. Patients with poor performance status (ECOG criteria of 3-4)~3. Serologic evidence of human immunodeficiency virus exposure~4. Patients with active uncontrolled infection. Patients that are HIV positive or test positive on HBs or HCV antigens.~5. Pregnant or lactating women~6. Serious medical or psychiatric illness which prevent informed consent~7. Patients who are likely to lost to follow up (eg, unwilling or difficult to return, cannot be contacted)~8. Patients with active malignancies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).